Epigenomics AG Receives MedTech Outlook’s 2019 Top 10 In-Vitro Diagnostics Award

BERLIN and SAN DIEGO, (GLOBE NEWSWIRE) — Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced today that it was selected by MedTech Outlook to receive the 2019 Top 10 In-Vitro Diagnostics Award. Conducted annually, the award recognizes companies that are excelling in their respective fields. The selection panel noted that through its unique, proprietary DNA methylation biomarker technology, Epigenomics is breaking new ground in bringing a portfolio of non-invasive, blood-based diagnostics that will facilitate the detection of cancer. The company’s flagship product, Epi proColon® is an innovative screening test for colorectal cancer using a simple blood draw and is available in the U.S., Europe and China. Epigenomics’ HCCBloodTest CE is available in Europe and is undergoing clinical evaluation for registration in the U.S.

“Physicians need new CRC screening options that can help improve compliance among the 30 million Americans who are unwilling or unable to get screened,” said Greg Hamilton, Chief Executive Officer of Epigenomics AG. “We believe that Epi proColon could help address the unmet medical need for new, non-invasive strategies for colorectal cancer detection.”

About Epi proColon®

Epi proColon® is indicated for colorectal cancer screening in average-risk patients who are unwilling or unable to perform colorectal cancer screening by colonoscopy and stool-based methods.

For patients, the test only requires a simple blood sample draw as part of routine healthcare provider visits. There are no dietary restrictions or alterations in medication required for the test. The sample will be analyzed at a national or regional diagnostic laboratory.

Epi proColon is recipient of the 2019 Excellence in Molecular Diagnostics by Corporate LiveWire’s Innovation and Excellence Awards. For more information on Epi proColon, visit www.epiprocolon.com.

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLungTM and HCCBloodTest, blood-based tests for lung and liver cancer detection, has received CE mark in Europe.

For more information, visit www.epigenomics.com.

Contact in the U.S.
David Bull
Director of Marketing 
Phone: 858.429.6199

Contact Epigenomics AG
Frederic Hilke 
IR.on AG
Phone +49 221 9140 970

Media Contact – Lazar Partners
Erich Sandoval